The clinical burden of xeroderma pigmentosum extends well beyond what is visible on the skin surface. Because the nucleotide excision repair pathway normally removes a wide range of bulky DNA lesions, patients with defects in this pathway accumulate damage not only from ultraviolet radiation but also from certain environmental mutagens encountered in daily life. The consequence is a progressive disease course in which early pigmentary changes give way to actinic damage, premalignant lesions, and invasive cancers at rates far exceeding those seen in the general population. Understanding why patients in complementation group A experience such a severe phenotype requires examining how the XPA protein coordinates the individual steps of the repair reaction, from damage recognition through dual incision and gap filling.

Nucleotide excision repair is mechanistically distinctive among DNA repair pathways because it does not recognize a single type of chemical lesion. Instead, it detects distortions in the DNA helix produced by diverse adducts, including the cyclobutane pyrimidine dimers and 6-4 photoproducts generated by ultraviolet light. This versatility comes at a cost: the pathway requires a large multiprotein assembly that must be recruited sequentially to the damage site, verified, and then handed off to the enzymatic components that carry out the incision steps. XPA, although it lacks catalytic activity of its own, sits at the center of this assembly process. It interacts with multiple NER factors and helps verify that a genuine lesion is present before the costly incision and resynthesis steps are undertaken. This checkpoint-like function means that even subtle defects in XPA can propagate through the entire pathway, impairing steps far downstream of the initial recognition event.

The distinction between processive and distributive mechanisms of action is central to understanding how repair proteins search for and act upon lesions embedded in chromatin. A distributive enzyme dissociates from DNA after each catalytic event and must rebind independently to find the next site, a strategy that becomes increasingly inefficient as the search space grows. A processive enzyme, by contrast, remains associated with its substrate through multiple consecutive events, sliding or stepping along the DNA molecule. In the crowded environment of the nucleus, where DNA is wrapped around histone octamers and folded into higher-order structures, the advantage of a processive search mechanism is substantial. A protein that can remain tethered to DNA while traversing nucleosome-bound regions has a far greater probability of encountering a lesion before dissociating than one that must repeatedly diffuse through three-dimensional space and rebind.

The proposal that XPA functions as a processivity factor for the endonucleases XPF and XPG reframes how these enzymes can be understood in the context of NER. XPF, in complex with ERCC1, carries out the 5′ incision, while XPG performs the 3′ incision that releases the damaged oligonucleotide. Both enzymes must locate the precise phosphodiester bonds flanking the lesion, positions that are determined by the geometry of the repair bubble rather than by the lesion itself. If these endonucleases operate distributively, as appears to be the case in XP-A cells, each incision event requires an independent encounter with the damaged site, and the efficiency of the dual incision reaction drops markedly. The observation that recombinant normal human XPA can correct this defect in XP-A cell extracts demonstrates that the processivity defect is directly attributable to the absence of functional XPA rather than to secondary changes that accumulate in these cells.

The structural basis for XPA’s role in processivity likely resides in its DNA binding domain, which spans multiple exons of the gene. Mutations in exons 3 and 5 that abolish XPA’s ability to enhance endonuclease processivity point to specific regions of the protein that are required for this function. The exon 5 mutation, identified in two patients with severe clinical presentations, provides a direct link between a defined molecular defect and the severity of disease. This kind of genotype-functional phenotype correlation is valuable because it moves beyond simply cataloging mutations and instead explains why particular amino acid changes produce particular clinical outcomes. It also suggests that the DNA binding domain of XPA is not merely a passive anchor but an active participant in coordinating the movement of repair enzymes along damaged DNA.

The challenge posed by nucleosomal DNA deserves particular attention. In vivo, approximately three-quarters of genomic DNA is packaged into nucleosomes at any given time, and the wrapping of DNA around the histone core restricts access by repair proteins. Lesions on the outward-facing surface of the nucleosome are more accessible than those facing the histone octamer, creating positional effects on repair efficiency. Chromatin-remodeling complexes can partially alleviate this barrier by repositioning or restructuring nucleosomes near damage sites, but the endonucleases themselves must still be able to function on DNA that is only transiently exposed. A processive mechanism of action may be especially advantageous in this context because it allows an enzyme to remain engaged with a stretch of chromatinized DNA long enough to complete incisions even when nucleosome repositioning is incomplete. The reduced incision of damaged nucleosomal DNA observed in XP-A cells is consistent with this interpretation and suggests that loss of XPA-mediated processivity compounds the inherent difficulty of repairing DNA in chromatin.

The involvement of the XPB/TFIIH translocase adds another dimension to the processivity model. TFIIH contains the XPB ATPase-translocase, which unwinds DNA around the lesion to generate the open bubble structure required for incision. Studies of XPA from the thermophilic fungus Chaetomium thermophilus indicate that XPA can increase the processivity of this translocase as it moves along UV-damaged DNA. The conservation of this function across eukaryotic evolution suggests that XPA’s role as a processivity factor is a fundamental feature of the NER pathway rather than a mammalian-specific adaptation. It also implies that the coordination between damage verification, bubble opening, and incision may depend on XPA’s ability to keep multiple enzymatic components engaged with the DNA substrate simultaneously.

From a therapeutic standpoint, the identification of specific molecular defects that correlate with clinical severity opens several possible avenues. If the loss of processivity in XP-A cells can be attributed to defined structural features of the mutant XPA protein, it may be possible to design small molecules or peptide mimetics that restore the missing function. Alternatively, gene therapy approaches aimed at delivering a functional copy of the XPA gene to affected tissues could, in principle, restore normal processivity to the endonucleases and improve repair of nucleosomal DNA. Even partial restoration of function might produce meaningful clinical benefit, given that the relationship between residual repair capacity and disease severity is not strictly linear. The development of such approaches will require continued effort to map the functional domains of XPA and to understand how each domain contributes to the overall coordination of the NER reaction in the context of chromatinized DNA.

The broader significance of these findings extends beyond XP-A. Other complementation groups involve proteins that also participate in the sequential assembly of the NER machinery, and defects in any of these components could similarly affect the processivity of downstream enzymes. Understanding how XPA confers processivity on XPF, XPG, and XPB/TFIIH may therefore illuminate general principles of how multi-protein repair complexes achieve efficiency on substrates that are chemically diverse and structurally occluded by chromatin. Such principles could be relevant to other DNA repair pathways that must operate on nucleosomal templates, and to the design of interventions that enhance repair capacity in contexts where it is compromised, whether through inherited mutation, age-related decline, or environmental exposure.

Subject of Research: XPA confers ability of endonucleases to act processively and to incise damaged nucleosomal DNA

Article Title: XPA confers ability of endonucleases to act processively and to incise damaged nucleosomal DNA

Article References: Lambert, M. W., & Lambert, W. C. (2026). XPA confers ability of endonucleases to act processively and to incise damaged nucleosomal DNA. Experimental Biology and Medicine, 251, Article 10902. https://doi.org/10.3389/ebm.2026.10902

Image Credits: AI Generated

DOI: 10.3389/ebm.2026.10902

Keywords: confers, ability, endonucleases, processively, incise, damaged, nucleosomal, scientific research